Literature DB >> 2540496

Biochemical basis for the interactions of type I and type II topoisomerases with DNA.

N Osheroff1.   

Abstract

DNA topoisomerases are complex and unique enzymes which alter the topological state of DNA without changing its chemical structure. Between the type I and II enzymes, topoisomerases carry out a multitude of reactions, including DNA binding, site specific DNA cleavage/religation, relaxation, catenation/decatenation, and knotting/unknotting of nucleic acid substrates, DNA strand transfer, and ATP hydrolysis. In vivo, topoisomerases are involved in many aspects of nucleic acid metabolism and play critical roles in maintaining chromosome and nuclear structure. Finally, these enzymes are of clinical relevance, as they appear to be the primary cellular targets for many varied classes of antineoplastic agents. Considering the importance of the topoisomerases, it is distressing that we know so little about their enzymatic mechanisms. Many major questions remain. Just a few include, "How do topoisomerases recognize their nucleic acid interaction sites?"; "What amino acid residues comprise the enzymes' active sites?"; "What are the conformational changes that accompany DNA strand passage?"; "How does phosphorylation stimulate enzyme activity?"; "How does topoisomerase function when it is part of an immobilized structure such as the nuclear matrix or the mitotic chromosome scaffold?"; and "How do antineoplastic agents interact with their topoisomerase targets and stabilize covalent enzyme.DNA cleavage products?" Clearly, before the physiological functions of the topoisomerases can be fully described, these and similar issues will have to be addressed. Hopefully, the next several years will produce answers for at least some of these important questions.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2540496     DOI: 10.1016/0163-7258(89)90108-3

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  39 in total

1.  Cloning and characterization of a cDNA encoding topoisomerase II in pea and analysis of its expression in relation to cell proliferation.

Authors:  M K Reddy; S Nair; K K Tewari; Y Mudgil; B S Yadav; S K Sopory
Journal:  Plant Mol Biol       Date:  1999-09       Impact factor: 4.076

2.  Drug Stimulated DNA Cleavage Mediated by Cauliflower Topoisomerase II.

Authors:  B S Sørensen; H Fukata; P S Jensen; A H Andersen; K Christiansen; H Fukasawa; O Westergaard
Journal:  Plant Physiol       Date:  1991-02       Impact factor: 8.340

3.  Autonomous parvovirus DNA replication requires topoisomerase I and its activity is increased during infection.

Authors:  M L Gu; S L Rhode
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

Review 4.  Antifungal agents: chemotherapeutic targets and immunologic strategies.

Authors:  N H Georgopapadakou; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

5.  Archaebacterial reverse gyrase cleavage-site specificity is similar to that of eubacterial DNA topoisomerases I.

Authors:  O I Kovalsky; S A Kozyavkin; A I Slesarev
Journal:  Nucleic Acids Res       Date:  1990-05-11       Impact factor: 16.971

Review 6.  In vitro assays used to measure the activity of topoisomerases.

Authors:  J F Barrett; J A Sutcliffe; T D Gootz
Journal:  Antimicrob Agents Chemother       Date:  1990-01       Impact factor: 5.191

Review 7.  Biochemical characteristics and physiological significance of major DNA topoisomerases.

Authors:  J A Sutcliffe; T D Gootz; J F Barrett
Journal:  Antimicrob Agents Chemother       Date:  1989-12       Impact factor: 5.191

8.  Recovery of the poisoned topoisomerase II for DNA religation: coordinated motion of the cleavage core revealed with the microsecond atomistic simulation.

Authors:  Nan-Lan Huang; Jung-Hsin Lin
Journal:  Nucleic Acids Res       Date:  2015-07-06       Impact factor: 16.971

9.  Lack of cross-resistance to fostriecin in a human small-cell lung carcinoma cell line showing topoisomerase II-related drug resistance.

Authors:  S de Jong; J G Zijlstra; N H Mulder; E G de Vries
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

10.  Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide.

Authors:  B Y Bugg; M K Danks; W T Beck; D P Suttle
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.